Skip to main content

Dr. John Sarantopoulos, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
29
In the NPI registry since
2005
Medicare patients seen, 2024
314

Licensed in Texas since 2004, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    TX license L8940 (first issued 2004; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
314
Services billed
52,593
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, oxaliplatin, 0.5 mg4,43012
Injection, pembrolizumab, 1 mg3,60014
Injection, fosaprepitant, 1 mg3,00015
Injection, ondansetron hydrochloride, per 1 mg76836
Injection, dexamethasone sodium phosphate, 1 mg68941
Injection, fluorouracil, 500 mg26317
Injection, palonosetron hcl, 25 mcg21016
Established patient office or other outpatient visit, 30-39 minutes208107
Injection, magnesium sulfate, per 500 mg16019
Injection of additional new drug or substance into vein15551

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 67 payments worth $57,957 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$32,059
Speaking at a medical education program$14,685
Travel and Lodging$8,405
Consulting Fee$1,780
Food and Beverage$1,013
Education$15.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 24, 2025Exelixis Inc.
Sep 24, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$5,940
Jun 30, 2025Pfizer Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,500
Jun 24, 2025Pfizer Inc.
Jun 24, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Apr 28, 2025Pfizer Inc.
Apr 28, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Jun 16, 2025Pfizer Inc.
Jun 16, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Jun 30, 2025Pfizer Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Oct 28, 2025Regeneron Healthcare Solutions, Inc.
Oct 28, 2025
Compensation for services other than consulting (speaking, faculty)
LIBTAYO · ONCOLOGY
$4,902
Mar 26, 2025Exelixis Inc.
Mar 26, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$4,455
Aug 12, 2025Exelixis Inc.
Aug 12, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Aug 19, 2025Exelixis Inc.
Aug 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
All 50 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Nov 6, 2025Aveo Pharmaceuticals, Inc.
Nov 6, 2025
Education
FOTIVDA · Oncology · in-kind
$15.00
Oct 28, 2025Regeneron Healthcare Solutions, Inc.
Oct 28, 2025
Compensation for services other than consulting (speaking, faculty)
LIBTAYO · ONCOLOGY
$4,902
Oct 24, 2025Regeneron Healthcare Solutions, Inc.
Oct 24, 2025
Compensation for services other than consulting (speaking, faculty)
LIBTAYO · ONCOLOGY
$1,157
Oct 16, 2025Pfizer Inc.
Oct 16, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Rosemont, IL · in-kind
$784
Oct 15, 2025Pfizer Inc.
Oct 15, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Rosemont, IL · in-kind
$197
Sep 24, 2025Exelixis Inc.
Sep 24, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$5,940
Sep 13, 2025Exelixis Inc.
Sep 13, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$211
Sep 13, 2025Exelixis Inc.
Sep 13, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$70.00
Sep 13, 2025Exelixis Inc.
Sep 13, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$70.00
Sep 13, 2025Exelixis Inc.
Sep 13, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL
$27.99
Aug 20, 2025Pfizer Inc.
Aug 20, 2025
Consulting Fee
PADCEV · ONCOLOGY
$1,080
Aug 19, 2025Exelixis Inc.
Aug 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Aug 12, 2025Exelixis Inc.
Aug 12, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,980
Aug 1, 2025Pfizer Inc.
Aug 1, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind
$636
Jul 18, 2025Exelixis Inc.
Jul 18, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind
$281
Jul 10, 2025Exelixis Inc.
Jul 10, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$330
Jun 30, 2025Pfizer Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,500
Jun 30, 2025Pfizer Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Jun 25, 2025Pfizer Inc.
Jun 25, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$452
Jun 24, 2025Pfizer Inc.
Jun 24, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Jun 24, 2025Pfizer Inc.
Jun 24, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind
$159
Jun 21, 2025Pfizer Inc.
Jun 21, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind
$224
Jun 19, 2025Pfizer Inc.
Jun 19, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Dallas, TX · in-kind
$14.13
Jun 18, 2025Pfizer Inc.
Jun 18, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$685
Jun 16, 2025Pfizer Inc.
Jun 16, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Jun 16, 2025Pfizer Inc.
Jun 16, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$200
Jun 16, 2025Pfizer Inc.
Jun 16, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$35.00
Jun 16, 2025Pfizer Inc.
Jun 16, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$18.99
Jun 10, 2025Pfizer Inc.
Jun 10, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind
$645
Jun 10, 2025Pfizer Inc.
Jun 10, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$207
Jun 7, 2025Pfizer Inc.
Jun 7, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind
$435
Apr 29, 2025Pfizer Inc.
Apr 29, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind
$140
Apr 29, 2025Pfizer Inc.
Apr 29, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind
$34.99
Apr 28, 2025Pfizer Inc.
Apr 28, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$5,125
Apr 26, 2025Pfizer Inc.
Apr 26, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind
$266
Apr 22, 2025Pfizer Inc.
Apr 22, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind
$207
Apr 15, 2025Pfizer Inc.
Apr 15, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind
$664
Mar 26, 2025Exelixis Inc.
Mar 26, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$4,455
Mar 24, 2025Exelixis Inc.
Mar 24, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$369
Mar 21, 2025Exelixis Inc.
Mar 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO
$34.99
Mar 20, 2025Exelixis Inc.
Mar 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$394
Mar 20, 2025Exelixis Inc.
Mar 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$70.00
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$357
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$234
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$70.00
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$70.00
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$69.99
Mar 12, 2025Exelixis Inc.
Mar 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind
$37.79
Mar 6, 2025Array Biopharma Inc
Mar 6, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$700
Feb 4, 2025Regeneron Healthcare Solutions, Inc.
Feb 4, 2025
Travel and Lodging
LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind
$32.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $3,846,455 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1a,1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination with Pembrolizumab i…
    Merck Sharp & Dohme LLC
  • An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
    Novartis Pharmaceuticals Corporation
  • A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
    Merck Sharp & Dohme LLC
  • Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
    Gilead Sciences, Inc.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in San Antonio

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 18, 2010), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1861495343. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.